Search research articles
Contact Us
Filters
Showing results (121-130 of 178) with videos related to
Page
of 18
Sort By:
Leukemia & Lymphoma
|
July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
British Journal of Haematology
|
January 6, 2016
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial
Philippe Armand, Haesook T Kim, Marie-Michele Sainvil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M Devine, Kouros Owzar, William Blum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 13, 2014
Outcomes after hematopoietic stem cell transplantation for children with I-cell disease
Troy C Lund, Sara S Cathey, Weston P Miller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 12, 2020
Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
Mary Eapen, Mei-Jie Zhang, Xiao-Ying Tang, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
Sara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation
|
February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas
Sara Singer, Nidhi Sharma, Robert Dean, et al.
JAMA Neurology
|
December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report
Richard A Nash, George J Hutton, Michael K Racke, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 178) with videos related to
Sort By:
Page
of 18
Leukemia & Lymphoma
|
July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
British Journal of Haematology
|
January 6, 2016
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial
Philippe Armand, Haesook T Kim, Marie-Michele Sainvil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M Devine, Kouros Owzar, William Blum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 13, 2014
Outcomes after hematopoietic stem cell transplantation for children with I-cell disease
Troy C Lund, Sara S Cathey, Weston P Miller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 12, 2020
Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
Mary Eapen, Mei-Jie Zhang, Xiao-Ying Tang, et al.
Haematologica
|
March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma
Sara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation
|
February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas
Sara Singer, Nidhi Sharma, Robert Dean, et al.
JAMA Neurology
|
December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report
Richard A Nash, George J Hutton, Michael K Racke, et al.
Page
of 18